No Relevant Relationship between Glucose Variability and Oxidative Stress in Well-Regulated Type 2 Diabetes Patients

Abstract

Background:

A strong relationship between glycemic variability and oxidative stress in poorly regulated type 2 diabetes (T2DM) on oral medication has been reported. However, this relationship was not seen in type 1 diabetes. The purpose of this study is to reexamine the relation between glycemic variability and oxidative stress in a cohort of T2DM patients on oral medication.

Methods:

Twenty-four patients with T2DM on oral glucose lowering treatment underwent 48 hours of continuous glucose monitoring (CGMS® System Gold™, Medtronic MiniMed) and simultaneous collection of two consecutive 24-hour urine samples for determination of 15(S)-8-iso-prostaglandin F_2α (PGF_2α) using high-performance liquid chromatography tandem mass spectrometry. Standard deviation (SD) and mean amplitude of glycemic excursions (MAGE) were calculated as markers of glycemic variability.

Results:

Included in the study were 66.7% males with a mean age (range) of 59 (36–76) years and a mean (SD) HbA1c of 6.9% (0.7). Median [interquartile range (IQR)] urinary 15(S)-8-iso-PGF_2α excretion was 176.1 (113.6–235.8) pg/mg creatinine. Median (IQR) SD was 31 (23–40) mg/dl and MAGE 85 (56–106) mg/dl. Spearman correlation did not show a significant relation for SD (ρ = 0.15, p = .49) or MAGE (ρ = 0.23, p = .29) with 15(S)-8-iso-PGF_2α excretion. Multivariate regression analysis adjusted for age, sex, HbA1c, and exercise did not alter this observation.

Conclusions:

We did not find a relevant relationship between glucose variability and 15(S)-8-iso-PGF_2α excretions in T2DM patients well-regulated with oral medication that would support an interaction between hyperglycemia and glucose variability with respect to the formation of reactive oxygen species.

Keywords

8-isoprostanes glucose variability MAGE oxidative stress type 2 diabetes

References

The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med.; 1993; 329 (14): 977–86.

Stratton

Adler

Neil

Matthews

Manley

Cull

Hadden

Turner

Holman

. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): Prospective observational study. BMJ. 2000; 321 (7258): 405–12.

Brownlee

. Biochemistry and molecular cell biology of diabetic complications. Nature. 2001; 414 (6865): 813–20.

The Diabetes Control and Complications Trial Research Group. The relationship of glycemic exposure (HbA1c) to the risk of development and progression of retinopathy in the diabetes control and complications trial. Diabetes.; 1995; 44 (8): 968–83.

Hirsch

Brownlee

. Should minimal blood glucose variability become the gold standard of glycemic control? J Diabetes Complications. 2005; 19 (3): 178–81.

Monnier

Mas

Ginet

Michel

Villon

Cristol

J P

Colette

. Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. JAMA. 2006; 295 (14): 1681–7.

Morrow

Hill

Burk

Nammour

Badr

Roberts

2nd . A series of prostaglandin F2-like compounds are produced in vivo in humans by a non-cyclooxygenase, free radical-catalyzed mechanism. Proc Natl Acad Sci. 1990; 87 (23): 9383–7.

Roberts

Morrow

. Measurement of F2-isoprostanes as an index of oxidative stress in vivo . Free Radic Biol Med. 2000; 28 (4): 505–13.

Wentholt

Kulik

Michels

Hoekstra

DeVries

. Glucose fluctuations and activation of oxidative stress in patients with type 1 diabetes. Diabetologia. 2008; 51 (1): 183–90.

10.

Proudfoot

Barden

Mori

Burke

Croft

Beilin

Puddey

. Measurement of urinary F(2)-isoprostanes as markers of in vivo lipid peroxidation-A comparison of enzyme immunoassay with gas chromatography/mass spectrometry. Anal Biochem. 1999; 272 (2): 209–15.

11.

Saenger

Laha

Edenfield

Sadrzadeh

. Quantification of urinary 8-iso-PGF2alpha using liquid chromatography-tandem mass spectrometry and association with elevated troponin levels. Clin Biochem. 2007; 40 (16–17): 1297–304.

12.

Monnier

Colette

Mas

Michel

Cristol

J P

Boegner

Owens

. Regulation of oxidative stress by glycaemic control: Evidence for an independent inhibitory effect of insulin therapy. Diabetologia. 2010; 53 (3): 562–71.

13.

Cockcroft

Gault

. Prediction of creatinine clearance from serum creatinine. Nephron. 1976; 16 (1): 31–41.

14.

Siegelaar

Holleman

Hoekstra

DeVries

. Glucose variability; does it matter? Endocr Rev. 2010; 31 (2): 171–82.

15.

Service

Molnar

Rosevear

Ackerman

Gatewood

Taylor

. Mean amplitude of glycemic excursions, a measure of diabetic instability. Diabetes. 1970; 19 (9): 644–55.

16.

Rohlfng

Wiedmeyer

Little

England

Tennill

Goldstein

. Defining the relationship between plasma glucose and HbA(1c): Analysis of glucose profiles and HbA(1c) in the Diabetes Control and Complications Trial. Diabetes Care. 2002; 25 (2): 275–8.

17.

Basu

Helmersson

. Factors regulating isoprostane formation in vivo . Antioxid Redox Signal. 2005; 7 (1–2): 221–35.

18.

Ceriello

Bortolotti

Motz

Crescentini

Lizzio

Russo

Tonutti

Taboga

. Meal-generated oxidative stress in type 2 diabetic patients. Diabetes Care. 1998; 21 (9): 1529–33.

19.

Davi

Ciabattoni

Consoli

Mezzetti

Falco

Santarone

Pennese

Vitacolonna

Bucciarelli

Costantini

Capani

Patrono

. In vivo formation of 8-iso-prostaglandin f2® and platelet activation in diabetes mellitus: Effects of improved metabolic control and vitamin E supplementation. Circulation. 1999; 99 (2): 224–9.

20.

Siegelaar

Kulik

van Lenthe

Mukherjee

Hoekstra

DeVries

. A randomized controlled trial comparing the effect of basal insulin and inhaled mealtime insulin on glucose variability and oxidative stress. Diabetes Obes Metab. 2009; 11 (7): 709–14.